J. Alan Diehl

Dr. J. Alan Diehl

Auto-generated profile, based on publicly available information

Dr. J. Alan Diehl


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2016 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
SQShuo Qie
Shuo Qie
JDJ. Alan Diehl
J. Alan Diehl

1 July 2019 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
FTFeven Tameire
Feven Tameire
IVIoannis I. Verginadis
Ioannis I. Verginadis
NLNektaria Maria Leli
Nektaria Maria Leli
CPChristine Polte
Christine Polte
CCCrystal S. Conn
Crystal S. Conn
CKConstantinos Koumenis
Constantinos Koumenis
The c-Myc oncogene drives malignant progression and induces robust anabolic and proliferative programmes leading to intrinsic stress. The mechanisms enabling adaptation to MYC-induced stress are not fully understood. Here we reveal an essential role for activating transcription factor 4 (ATF4) in survival following MYC activation. MYC upregulates ATF4 by activating general control nonderepressible 2 (GCN2) kinase through uncharged transfer RNAs. Subsequently, ATF4 co-occupies promoter regions of over 30 MYC-target genes, primarily those regulating amino acid and protein synthesis, including eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), a negative regulator of translation. 4E-BP1 relieves MYC-induced proteotoxic stress and is essential to balance protein synthesis. 4E-BP1 activity is negatively regulated by mammalian target of rapamycin complex 1 (mTORC1)-dependent phosphorylation and inhibition of mTORC1 signalling rescues ATF4-deficient cells from MYC-induced endoplasmic reticulum stress. Acute deletion of ATF4 significantly delays MYC-driven tumour progression and increases survival in mouse models. Our results establish ATF4 as a cellular rheostat of MYC activity, which ensures that enhanced translation rates are compatible with survival and tumour progression.

28 May 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
GWGabrielle S. Wong
Gabrielle S. Wong
JZJin Zhou
Jin Zhou
JLJie Bin Liu
Jie Bin Liu
ZWZhong Wu
Zhong Wu
XXXinsen Xu
Xinsen Xu
ABAdam J. Bass
Adam J. Bass

2 June 2022 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
IVIoannis I. Verginadis
Ioannis I. Verginadis
HAHarris Avgousti
Harris Avgousti
JMJames Monslow
James Monslow
GSGiorgos Skoufos
Giorgos Skoufos
FCFrank Chinga
Frank Chinga
CKConstantinos Koumenis
Constantinos Koumenis
Bidirectional signalling between the tumour and stroma shapes tumour aggressiveness and metastasis. ATF4 is a major effector of the Integrated Stress Response, a homeostatic mechanism that couples cell growth and survival to bioenergetic demands. Using conditional knockout ATF4 mice, we show that global, or fibroblast-specific loss of host ATF4, results in deficient vascularization and a pronounced growth delay of syngeneic melanoma and pancreatic tumours. Single-cell transcriptomics of tumours grown in Atf4Δ/Δ mice uncovered a reduction in activation markers in perivascular cancer-associated fibroblasts (CAFs). Atf4Δ/Δ fibroblasts displayed significant defects in collagen biosynthesis and deposition and a reduced ability to support angiogenesis. Mechanistically, ATF4 regulates the expression of the Col1a1 gene and levels of glycine and proline, the major amino acids of collagen. Analyses of human melanoma and pancreatic tumours revealed a strong correlation between ATF4 and collagen levels. Our findings establish stromal ATF4 as a key driver of CAF functionality, malignant progression and metastasis.

5 February 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
NSNatalia Siwecka
Natalia Siwecka
WRWioletta Rozpędek-Kamińska
Wioletta Rozpędek-Kamińska
AWAdam Wawrzynkiewicz
Adam Wawrzynkiewicz
DPDariusz Pytel
Dariusz Pytel
JDJ. Alan Diehl
J. Alan Diehl
IMIreneusz Majsterek
Ireneusz Majsterek
Inositol-requiring enzyme type 1 (IRE1) is a serine/threonine kinase acting as one of three branches of the Unfolded Protein Response (UPR) signaling pathway, which is activated upon endoplasmic reticulum (ER) stress conditions. It is known to be capable of inducing both pro-survival and pro-apoptotic cellular responses, which are strictly related to numerous human pathologies. Among others, IRE1 activity has been confirmed to be increased in cancer, neurodegeneration, inflammatory and metabolic disorders, which are associated with an accumulation of misfolded proteins within ER lumen and the resulting ER stress conditions. Emerging evidence suggests that genetic or pharmacological modulation of IRE1 may have a significant impact on cell viability, and thus may be a promising step forward towards development of novel therapeutic strategies. In this review, we extensively describe the structural analysis of IRE1 molecule, the molecular dynamics associated with IRE1 activation, and interconnection between it and the other branches of the UPR with regard to its potential use as a therapeutic target. Detailed knowledge of the molecular characteristics of the IRE1 protein and its activation may allow the design of specific kinase or RNase modulators that may act as drug candidates.

14 April 2021 in Nature
Verified
Journal Article
Closed access
PDF file
ACAndrea C. Chaikovsky
Andrea C. Chaikovsky
CLChuan Li
Chuan Li
EJEdwin E. Jeng
Edwin E. Jeng
SLSamuel Loebell
Samuel Loebell
MLMyung Chang Lee
Myung Chang Lee
JSJulien Sage
Julien Sage